Press release
Epilepsy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2024 (Updated)
Epilepsy Pipeline
Key Takeaways from the Epilepsy Pipeline Report
• DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
• The leading companies working in the Epilepsy market include UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
• Promising Epilepsy Pipeline Therapies in the various stages of development include topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
Request a sample and discover the recent advances in Epilepsy Treatment Drugs @ Epilepsy Pipeline Report- https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Epilepsy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Epilepsy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Epilepsy clinical trial landscape.
Epilepsy Overview
Epilepsy is one of the most common serious brain conditions, affecting over 50 million people worldwide. Epilepsy is a neurological disorder that is characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological, and social consequences.
Find out more about Epilepsy Treatment Drugs @ Drugs for Epilepsy Treatment- https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Epilepsy Emerging Drugs Profile
• ZX008 (Fenfluramine Hydrochloride): UCB
• Cenobamate: SK Life Science, Inc.
• STK-001: Stoke Therapeutics
• EPX-100: Epygenix
• NRTX-1001: Neurona Therapeutics
• BMB-101: Bright Minds Biosciences
Epilepsy Pipeline Therapeutics Assessment
The Epilepsy pipeline report proffers an integral view of the Epilepsy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
DelveInsight's Epilepsy Pipeline report covers around 90+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Epilepsy Pipeline Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Epilepsy Pipeline Therapies @ Epilepsy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Epilepsy Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
• Epilepsy Pipeline Therapies- topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
Dive deep into rich insights for new drugs for Epilepsy Treatment, Visit @ Epilepsy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Epilepsy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Epilepsy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ZX008 (Fenfluramine Hydrochloride): UCB
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. STK-001: Stoke Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BMB-101: Bright Minds Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. NT102: Neuroene Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Epilepsy Key Companies
21. Epilepsy Key Products
22. Epilepsy- Unmet Needs
23. Epilepsy- Market Drivers and Barriers
24. Epilepsy- Future Perspectives and Conclusion
25. Epilepsy Analyst Views
26. Epilepsy Key Companies
27. Appendix
For further information on the Epilepsy Pipeline therapeutics, reach out to Epilepsy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epilepsy Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2024 (Updated) here
News-ID: 3481230 • Views: …
More Releases from DelveInsight Business Research LLP
Pharmaceutical Contract Manufacturing Market Forecast Report 2032: Size, Share, …
DelveInsight's Pharmaceutical Contract Manufacturing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceutical Contract Manufacturing Companies market shares, challenges, Pharmaceutical Contract Manufacturing Market Drivers, barriers, trends, and key market Pharmaceutical Contract Manufacturing companies in the market.
To read more about the latest highlights related to the Pharmaceutical Contract Manufacturing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…
Pharmaceuticals Market Forecast Report 2032: Size, Share, and Strategic Insights …
DelveInsight's Pharmaceuticals Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceuticals Companies market shares, challenges, Pharmaceuticals Market Drivers, barriers, trends, and key market Pharmaceuticals companies in the market.
To read more about the latest highlights related to the Pharmaceuticals Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pharmaceuticals Market Report
• In July 2025, Sanofi announced the…
Checkpoint Inhibitors Competitive Landscape Report 2025: Emerging Therapies, Lea …
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2025" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…
Surgical Simulation Market Forecast Report 2032: Size, Share, and Strategic Insi …
DelveInsight's Surgical Simulation Market Insights Report 2032 provides the current and forecast market analysis, individual leading Surgical Simulation Companies market shares, challenges, Surgical Simulation Market Drivers, barriers, trends, and key market Surgical Simulation companies in the market.
To read more about the latest highlights related to the Surgical Simulation Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/surgical-simulation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Surgical Simulation Market…
More Releases for Epilepsy
Adult mitochondrial epilepsy presentation
Mitochondrial epilepsy is a rare but severe neurological condition caused by genetic mutations that impair mitochondrial function, disrupting cellular energy production in the brain. Patients often present with seizures, developmental delays, and neurodegeneration. It is closely associated with broader mitochondrial diseases such as MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) and Leigh syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72869
Due to its rarity and complexity, treatment options…
Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global…
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Epilepsy Market are:
• Idexx Laboratories Inc.
• PBD Biotech Ltd
• Thermo Fisher Scientific Inc.
• Innovative Diagnostics SAS
• Neogen Corp
• Enfer Labs
• bioMerieux SA
• Ring Biotechnology Co Ltd
• Bionote Inc.
• Shenzhen Bioeasy Biotechnology Co Ltd.
Contact Us:
If you have any queries about this report or if…
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims…
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821
Epilepsy devices play…
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
This…
